| Charite Medical University of Berlin commences Mologen renal cancer drug study - Pharmaceutical Business Review |
|
|
Pharmaceutical Business Review The Charite - Medical University of Berlin has begun the implementation of the clinical study phase I/II with Mologen's renal cancer medication MGN1601 |